Scott M. Rocklage is well known for his affiliation with 5AM Ventures. He joined the company in 2003 before becoming a managing partner the year after. Apart from his relation with the company, he was also responsible for the approval of new drug applications by the FDA, namely Cubicin, Teslascan and Omniscan.
His experience in the healthcare industry has shown exceptional strategic leadership and healthcare management skills to the world today, which has also proven fundamental in overseeing multiple clinical trials. Dr. Rocklage has held different positions in research and development at Catalytica and Salutar. He was also the CEO and board chairperson of Cubist Pharmaceuticals not to mention the CEO and president of Nycomed Salutar. As of 2017, he was the board chairperson of Pulmatrix (NASDAQ: PULM), Epirus (NASDAQ: EPRS), Cidara (NASDAQ:CDTX), Kinestral and Rennovia.
Rocklage pursued his first degree in chemistry when he joined the University of California. He later on pursued a doctorate degree in chemistry at Massachusetts Institute of Technology. Due to doctorate research, he won a Nobel Prize that acknowledged his contribution to the pharmaceutical industry. Since then, he has authored and invented at least 100 peer-reviewed publication and 30 U.S. patents respectively. Dr. Rocklage has his office in Boston, MA.
The idea of business came in when he was interested in venture capitalism. As such, 5AM Ventures is a science-based venture capital company that is still on its early stages. For Dr. Rocklage, his days are highly varied depending on what he wants to accomplish. For instance, he could decide to study new developments and trends in life science today but move on to working with 5AM Ventures’ management team on portfolios the next day. In other days, he is scheduled for board meetings and for some, he just takes a day off from the hustle and bustle.
However, his idea of an exciting day is when he gets to work with business executives, physicians and other scientists on ways that could potentially define the change for many unmet medical needs. For example, Dr. Rocklage concerns himself with the growth taking place in cancer research where he reiterates that more genotypes and specific mutations are being identified. He is excited that researchers are getting closer to the solution for this dreadful disease.
Dr. Rocklage accrues his success to discipline in time management, appropriate prioritization and calendaring. His desire is to keep on focusing on solutions that bring more benefits to humanity.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.